コンテンツへスキップ
Merck
  • The nuclear piston activates mechanosensitive ion channels to generate cell migration paths in confining microenvironments.

The nuclear piston activates mechanosensitive ion channels to generate cell migration paths in confining microenvironments.

Science advances (2021-02-02)
Hong-Pyo Lee, Farid Alisafaei, Kolade Adebawale, Julie Chang, Vivek B Shenoy, Ovijit Chaudhuri
要旨

Cell migration in confining microenvironments is limited by the ability of the stiff nucleus to deform through pores when migration paths are preexisting and elastic, but how cells generate these paths remains unclear. Here, we reveal a mechanism by which the nucleus mechanically generates migration paths for mesenchymal stem cells (MSCs) in confining microenvironments. MSCs migrate robustly in nanoporous, confining hydrogels that are viscoelastic and plastic but not in hydrogels that are more elastic. To migrate, MSCs first extend thin protrusions that widen over time because of a nuclear piston, thus opening up a migration path in a confining matrix. Theoretical modeling and experiments indicate that the nucleus pushing into the protrusion activates mechanosensitive ion channels, leading to an influx of ions that increases osmotic pressure, which outcompetes hydrostatic pressure to drive protrusion expansion. Thus, instead of limiting migration, the nucleus powers migration by generating migration paths.

材料
製品番号
ブランド
製品内容

Roche
cOmplete、ミニ、EDTA フリー、プロテアーゼ阻害剤カクテル, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
ノコダゾール, ≥99% (TLC), powder
Sigma-Aldrich
DL-グリセルアルデヒド 3-リン酸 溶液, 45-55 mg/mL in H2O
Sigma-Aldrich
5-(N-エチル-N-イソプロピル)アミロライド
Sigma-Aldrich
Fluo 3, suitable for fluorescence, ~70%
Sigma-Aldrich
Anti-Myosin Light Chain Antibody, phospho-specific (Ser19), Chemicon®, from rabbit
Sigma-Aldrich
MISSION® esiRNA, targeting human VIM
Sigma-Aldrich
MISSION® esiRNA, targeting human LMNA
Sigma-Aldrich
MISSION® esiRNA, targeting human SLC9A1
Sigma-Aldrich
MISSION® esiRNA, targeting human TRPV4